‘Elbrit Life Sciences’, a new pharmaceutical company based in Mumbai, India, today opened gates for business in India. The company would be serving the South Indian states initially and aims to cover the entire country with time. According to the sources, the company would be targeting cardiac and diabetes product segments in the present year. Elbrit Life Sciences is a part of a global business group based in UK with investments in science, research and education. The group has significantly invested in next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.

Combination of Palbociclib with Letrozole significantly prolonging progression of tumor compared with single letrozole in post-menopausal women with estrogen receptor positive. This details resulted from PALOMA-1 study which is a Phase 2 trial designed to assess progression-free survival in post-menopausal women with ER+, HER2- advanced breast cancer receiving palbociclib in combination with letrozole versus letrozole alone.

Recently, U.S. Food and Drug Administration approved Oralair, first sublingual allergen extract approved in the United States, to treat allergic rhinitis with or without conjunctivitis that is induced by certain grass pollens in age group of 10 to 65 years. Oralair contains a mixture of freeze-dried extracts from the pollens of five grasses, including Kentucky Blue Grass, Orchard, Perennial Rye, Sweet Vernal and Timothy.

The U.S. Food and Drug Administration approved Otezla (apremilast), manufactured for Celgene Corporation, Summit, N.J.,  to treat adults with active psoriatic arthritis (PsA), which is a form of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with PsA. Joint pain, stiffness and swelling are the main signs and symptoms of PsA.